Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma

Michel Bila(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Amelie Franken(VIB-KU Leuven Center for Cancer Biology), Jeroen Meulemans(KU Leuven), Melisa Garip(KU Leuven), Ann Hoeben(Maastricht University Medical Centre), Vincent Vander Poorten(KU Leuven), Robin Willaert(KU Leuven), Jeroen Van Dessel(Universitair Ziekenhuis Leuven)
Oral Oncology
December 18, 2023
10.1016/j.oraloncology.2023.106664
Cited by 13

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
|The Lancet|2017|401